- This event has passed.
WEBINAR: Psychiatry and Psychedelics
Wednesday May 20 @ 7:30 pm - 8:30 pmFree
Join this free, 60-minute online webinar to gain access to insights and learn about ground breaking treatments to chronic mental health conditions.
There is a lot of positive discussion currently about the possibilities of treating psychiatric patients with psychedelic-assisted psychotherapy.
But how well will the discipline of psychiatry adapt to the current psychedelic narrative and what changes in attitudes and processes will psychiatry have to make to accept psychedelic medicines as part of its therapeutic armamentarium?
Remember too that the use of psychedelics in psychiatry went wrong once before. How can we make sure this doesn’t happen again?
These and other questions about the merging of these two great narratives will be discussed by Dr Nigel Strauss in this webinar.
Date: Wednesday, 20 May, 2020
Time: 7:25pm for 7:30pm start – 8:30pm (incl Q&A) (AEST)
The presentation WILL BEGIN AT 7:30pm.
Location: Online. A link will be emailed to you with the viewing details once you have registered.
Following the presentation there will be a Q & A panel with Dr Nigel Strauss. This will be an opportunity to engage in a discussion about psychedelic-assisted psychotherapies for mental illness broadly, and what Mind Medicine Australia and other local organisations are doing here in Australia.
More about medicinal psychedelic treatments:
Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.
The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.
More about the presenters
Dr Nigel Strauss
MBBS, DPM, FRANZCP
Nigel Strauss has been a Consultant Psychiatrist for over 40 years and is the Medical Director of the Millswyn Clinic in South Yarra, a private outpatient psychiatric facility. Dr Strauss is an Honorary Research Fellow within Psychiatry, University of Melbourne and a Member of Scientific Advisory Board, European Foundation for Psychedelic Science. Dr Strauss is also a Member of Scientific and Medical Advisory Board, Australian Institute for Medicinal Cannabis. He has a special interest in medico-legal psychiatry and is employed as a lecturer by AMA Victoria. He has been a Consultant to Worksafe and TAC. Dr Strauss has a special interest in psychedelic medicines and has trained in the UK to work as a psychedelic therapist and is also a MAPS accredited psychedelic therapist. He is an advocate for psychedelic-assisted psychotherapy research in Australia.
Support psychedelic research and therapy development
By donating to Mind Medicine Australia, you will be helping us to accelerate the availability and best practice of psychedelic-assisted psychotherapy in Australia. We are a small organisation doing big things – we need your support.
Please click here to make a tax-deductible donation.
Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes.
Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms.
You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms (for example facebook, instagram and zoom private and public chat forms during the webinar).
Breaches of these guidelines may result in not being able to participate in the event.
We thank you for support and cooperation on these matters.